Story
Omeros Stock Surges on Surprise Q2 Profit, YARTEMLEA Sales Double Estimates

Shares of Omeros Corp. (OMER) surged more than 17% in pre-market trading after the company reported second-quarter financial results that significantly beat Wall Street expectations, posting a surprise profit fueled by rapidly accelerating sales of its flagship drug, YARTEMLEA.
Blockbuster Quarter Shatters Expectations
Omeros announced total revenue of $28.5 million for the second quarter, more than double the consensus analyst forecast of $12.67 million, according to its earnings release. The company also reached a major financial milestone by reporting its first-ever GAAP net income, which stood at $13.2 million, or $0.18 per share.
On an adjusted basis, Omeros reported earnings per share of $0.02. This marked a dramatic reversal from the anticipated net loss of $0.25 per share that analysts had projected, signaling a significant shift in the company's financial health.
YARTEMLEA Sales Drive Growth
AdThe strong performance was almost entirely driven by YARTEMLEA, an FDA-approved lectin pathway complement inhibitor used to treat a rare complication associated with hematopoietic stem cell transplants. The drug's net revenue reached $28.5 million, a 188% sequential increase from the first quarter.
This rapid commercial uptake allowed Omeros to achieve positive operating cash flow for the first time, a key indicator of financial sustainability for investors. The company's outlook is further supported by a permanent CMS J-code for YARTEMLEA, which facilitates reimbursement, and an active reduction of its convertible debt load.
Market Reaction
Investors responded enthusiastically to the unexpectedly strong quarter. The stock jumped 17.1% in pre-open trading, as reported by Investing.com, bringing its price near its 52-week high of $17.65. The move highlights a significant shift in investor sentiment, which had previously seen the stock trade as low as $3.94 over the past year.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.